IP Library › Granted Patent US 11,911,617
Granted Patent B2
US 11,911,617 · App. 16/897,171 · Granted Feb 27, 2024

Methods for treatment of disease using galvanic vestibular stimulation

Inventors: Paul Duncan McGeoch (Del Mar, CA); Vilayanur S. Ramachandran (San Diego, CA)
Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A61N1/36014A61N1/0408A61N1/0456A61N1/36031
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,911,617
App. No.
16/897,171
Granted
Feb 27, 2024
Kind
B2
Abstract

Methods are provided for treating diseases by altering body mass composition in a human subject through application of galvanic vestibular stimulation (GVS) using electrodes placed in electrical contact with the subject's scalp at a location corresponding to each of the subject's left and right vestibular systems. The methods may be used to treat obesity-related diseases such as diabetes, hypertension, type 2 diabetes mellitus and osteoporosis. GVS may be applied for a predetermined period of time at regular intervals.

Claims (14)

1. A method for altering body mass composition in a human subject, the method comprising:

connecting the subject with a device which produces an alternating polarity electrical current by disposing electrodes at the subject's scalp at a location corresponding to each of the subject's left and right vestibular systems; and

applying galvanic vestibular stimulation (GVS) from the device to the subject via the electrodes to maintain a constant current across the subject's scalp to alter body mass composition.

2. The method of claim 1 , wherein altering body mass composition comprises decreasing total body fat, increasing relative percentage lean muscle mass, and increasing bone mineral density in the human subject.

3. The method of claim 2 , wherein altering body mass composition treats at least one of diabetes, type 2 diabetes mellitus, hypertension, obesity, osteoporosis, and an obesity-related disease.

4. The method of claim 1 , wherein applying GVS comprises using an AC square wave at approximately 0.5 Hz with an approximately 50 percent duty cycle.

5. The method of claim 1 , wherein applying GVS comprises applying GVS for a predetermined period of time at regular intervals.

6. A method for treating at least one disease in a human subject, the method comprising:

connecting the subject with a device which produces an alternating polarity electrical current by disposing electrodes at the subject's scalp at a location corresponding to each of the subject's left and right vestibular systems; and

treating the at least one disease by applying galvanic vestibular stimulation (GVS) from the device to the subject via the electrodes to maintain a constant current across the subject's scalp, wherein the at least one disease is one or more of diabetes, type 2 diabetes mellitus, hypertension, obesity, osteoporosis, or an obesity-related disease.

7. The method of claim 6 , wherein applying GVS to the subject alters body mass composition.

8. The method of claim 7 , wherein altering body mass composition comprises decreasing total body fat, increasing relative percentage lean muscle mass, and increasing bone mineral density in the human subject.

9. The method of claim 6 , wherein applying GVS comprises using an AC square wave at approximately 0.5 Hz with an approximately 50 percent duty cycle.

10. The method of claim 6 , wherein applying GVS comprises applying GVS for a predetermined period of time at regular intervals.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 11, 2020
From: RAMACHANDRAN, VILAYANUR S.; MCGEOCH, PAUL DUNCAN
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 052902/0073 →
Continuity (4)
Continuation 15644727 · Jul 7, 2017
Continuation In Part 14770333
Provisional Application 61771766 · Mar 1, 2013
Related Publication 20200306535A1 · Oct 1, 2020
Cited By (1)
US 12,364,860